The 95 cases involved 15 people 65 or older and 20 people who were Hispanic, Black, Asian or multinational. The company stated that the vaccine is equally safe and effective in all subgroups.
The results were analyzed by an independent data security monitoring board, which was appointed by the National Institutes of Health.
Modern, based in Cambridge, Mass., Developed its vaccine in collaboration with researchers at the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases.
The director of the institute, Dr. Anthony S. Fauci said in an interview: “I was saying that I would be satisfied with the 75 percent effective vaccine. Aspiring, you’d like to see 90, 95 percent, but I didn’t expect that. I thought we would be good, but 94.5 percent is very impressive.
In a news briefing on Monday, the director of the National Institutes of Health, Drs. Fauci and Drs. Francis Collins insisted that the expected news did not mean that people would not let their guard down. On the contrary, he “double downed” the public to wear masks, remove, wash hands and avoid crowds, and maintain that course. Until the vaccine is available.
Modern chief executive Stephen Bansell said in a statement that the results provided “the first clinical recognition that our vaccine could prevent Kovid-19 disease, including critical illness.”
Pfizer’s Chief Executive Officer, Drs. Albert Boula, Tweeted and congratulated From modern to.
Pfizer and Modern each announced the findings in a news release, not in peer-reviewed scientific journals, and the companies have yet to disclose detailed data that would allow outside experts to evaluate their claims. Therefore, the results cannot be considered conclusive. Studies continue, and statistics on effectiveness may change.